- Home
- GANX vs BRNS Comparison
GANX vs BRNS Comparison
Compare GANX & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GANX
- BRNS
- Stock Information
- Founded
- GANX 2017
- BRNS 2016
- Country
- GANX United States
- BRNS United Kingdom
- Employees
- GANX N/A
- BRNS N/A
- Industry
- GANX Biotechnology: Pharmaceutical Preparations
- BRNS Biotechnology: Pharmaceutical Preparations
- Sector
- GANX Health Care
- BRNS Health Care
- Exchange
- GANX Nasdaq
- BRNS Nasdaq
- Market Cap
- GANX 41.9M
- BRNS 36.7M
- IPO Year
- GANX 2021
- BRNS 2021
- Fundamental
- Price
- GANX $1.54
- BRNS $1.04
- Analyst Decision
- GANX Strong Buy
- BRNS Strong Buy
- Analyst Count
- GANX 5
- BRNS 2
- Target Price
- GANX $7.60
- BRNS $4.00
- AVG Volume (30 Days)
- GANX 204.1K
- BRNS 59.3K
- Earning Date
- GANX 11-14-2024
- BRNS 11-06-2024
- Dividend Yield
- GANX N/A
- BRNS N/A
- EPS Growth
- GANX N/A
- BRNS N/A
- EPS
- GANX N/A
- BRNS N/A
- Revenue
- GANX N/A
- BRNS $14,969,000.00
- Revenue This Year
- GANX N/A
- BRNS $1,805.74
- Revenue Next Year
- GANX N/A
- BRNS N/A
- P/E Ratio
- GANX N/A
- BRNS N/A
- Revenue Growth
- GANX N/A
- BRNS 106.21
- 52 Week Low
- GANX $0.89
- BRNS $0.80
- 52 Week High
- GANX $5.33
- BRNS $4.16
- Technical
- Relative Strength Index (RSI)
- GANX 39.69
- BRNS 50.96
- Support Level
- GANX $1.59
- BRNS $0.80
- Resistance Level
- GANX $1.70
- BRNS $1.05
- Average True Range (ATR)
- GANX 0.15
- BRNS 0.13
- MACD
- GANX -0.00
- BRNS 0.02
- Stochastic Oscillator
- GANX 10.15
- BRNS 54.44
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.